Signal transduction pathways are modular composites of functionally interdependent sets of proteins that act in a coordinated fashion to transform environmental information into a phenotypic response. The pro-inflammatory cytokine tumour necrosis factor (TNF)-alpha triggers a signalling cascade, converging on the activation of the transcription factor NF-kappa B, which forms the basis for numerous physiological and pathological processes. Here we report the mapping of a protein interaction network around 32 known and candidate TNF-alpha/NF-kappa B pathway components by using an integrated approach comprising tandem affinity purification, liquid-chromatography tandem mass spectrometry, network analysis and directed functional perturbation studies using RNA interference. We identified 221 molecular associations and 80 previously unknown interactors, including 10 new functional modulators of the pathway. This systems approach provides significant insight into the logic of the TNF-alpha/NF-kappa B pathway and is generally applicable to other pathways relevant to human disease.
Antibodies that block the ligand binding site of the cation‐dependent mannose 6‐phosphate specific receptor (Mr 46,000 MPR) were used to probe the function of the receptor in transport of lysosomal enzymes. Addition of the antibodies to the medium of Morris hepatoma 7777 cells, which express only the Mr 46,000 MPR, resulted in a decreased intracellular retention and increased secretion of newly synthesized lysosomal enzymes. In fibroblasts and HepG2 cells that express the cation‐independent mannose 6‐phosphate specific receptor (Mr 215,000 MPR) in addition to the Mr 46,000 MPR, antibodies against the Mr 46,000 MPR inhibited the intracellular retention of newly synthesized lysosomal enzymes only when added to the medium together with antibodies against the Mr 215,000 MPR. Morris hepatoma (M.H.) 7777 did not endocytose lysosomal enzymes, while U937 monocytes, which express both types of MPR, internalized lysosomal enzymes. The uptake was inhibited by antibodies against the Mr 215,000 MPR, but not by antibodies against the Mr 46,000 MPR. These observations suggest that Mr 46,000 MPR mediates transport of endogenous but not endocytosis of exogenous lysosomal enzymes. Internalization of receptor antibodies indicated that the failure to mediate endocytosis of lysosomal enzymes is due to an inability of surface Mr 46,000 MPR to bind ligands rather than its exclusion from the plasma membrane or from internalization.
SUMMARY While recombinant human erythropoietin (rhEpo) has been widely used to treat anemia in cancer patients, concerns about its adverse effects on patient survival have emerged. A lack of correlation between expression of the canonical EpoR and rhEpo’s effects on cancer cells prompted us to consider the existence of an alternative Epo receptor. Here, we identified EphB4 as an Epo receptor that triggers downstream signaling via STAT3 and promotes rhEpo induced tumor growth and progression. In human ovarian and breast cancer samples, expression of EphB4 rather than the canonical EpoR correlated with decreased disease-specific survival in rhEpo-treated patients. These results identify EphB4 as a critical mediator of erythropoietin-induced tumor progression and further provide clinically significant dimension to the biology of erythropoietin.
Synthesis of the cation-dependent mannose 6-phosphate-specific receptor was followed in cells of human (fibroblasts, Hep G2 cells, U937 monocytes, blood-derived macrophages) or rat (Morris hepatoma 7777 cells), origin. The mature form of the receptor has an apparent molecular size of 46 kDa except in fibroblasts, where the apparent molecular size was 43 kDa. The receptor contains 7-8 N-linked oligosaccharide chains, about 5 of which are converted into endo -resistant forms within 2 h of synthesis. A small fraction of the receptor (about 3% of total in U937 monocytes) is located at the cell surface while the bulk of the receptor resides in internal membranes. Part of the internal receptors (20% in fibroblasts) resides in membranes of the endocy tic pathway. The receptor was not detectable in dense lysosomes. The receptor is a hydrophobic transmembrane protein partitioning with Triton X-l 14. The cy tosolic portion of the receptor comprises a molecular size of about 5 kDa and contains the C-terminus. The luminal (or external) portion of the receptor comprises a molecular size of > 37.5 kDa, of which more than half is represented by carbohydrate. Cross-linking experiments suggest that the mature receptor exists in membranes as a dimer. 46-kDa-Mannose-6-phosphat-spezifischer Rezeptor: Biosynthese, Processing, subzelluläre Lokalisation und Topologie Zusammenfassung: In verschiedenen menschlichen Zellinien (Fibroblasten, Hep G2-Zellen, U937 Monocyten, Makrophagen) und MorrisHepatoma 7777-Zellen der Ratte wurde die Biosynthese des Kationen-abhängigen Mannose-6-phosphat-spezifischen Rezeptors untersucht. Der reife Rezeptor hat in Fibroblasten eine Molekularmasse von 43 kDa und in den übrigen Zellen eine Molekularmasse von 46 kDa. Der Rezeptor enthält 7-8 Asparagin-verknüpfte Oligosaccharide, von denen ca. 5 innerhalb von 2 h nach der Synthese in Endo-H-resistente Formen umgewandelt werden. Der Rezeptor ist größtenteils in intrazellulären Membranen lokalisiert. Ein Teil der intrazellulären Rezeptoren (20% in Fibroblasten) ist in Membranen des
Recombinant sorbitol dehydrogenase (SDH) from Rhodobacter sphaeroides has been crystallized in the absence of the cofactor NAD(H) and its structure determined to 2.4 A resolution using molecular replacement (refined R and R free factors of 18.8 and 23.8%, respectively). As expected from the sequence and shown by the conserved fold, SDH can be assigned to the short-chain dehydrogenase/reductase protein family. The cofactor NAD and the substrate sorbitol have been modelled into the structure and the active-site architecture, which displays the highly conserved catalytic tetrad of Asn-Ser-Tyr-Lys residues, is discussed in relation to the enzyme mechanism. This is the first structure of a bacterial SDH belonging to the SDR family.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.